Kuchla

Strychnos nux-vomica

Kuchla (Strychnos nux-vomica) is a significant herb in Ayurveda, known for its highly potent seeds. Traditionally, it's used with extreme caution for its supposed stimulant properties. It is claimed to balance Vata and Pitta doshas while increasing Kapha. This deciduous tree is native to Southeast Asia.

PLANT FAMILY

Loganiaceae (Logania)

PARTS USED

Seed, Root

AYURVEDIC ACTION

Vata ↓, Pitta ↓, Kapha ↑

ACTIVE COMPOUNDS

Strychnine (1-3%)

What is Kuchla?

Kuchla, scientifically known as Strychnos nux-vomica, is a deciduous tree native to Southeast Asia and Australia, belonging to the Loganiaceae family. Characterized by its small, round, and highly poisonous seeds, it has been historically recognized for the potent alkaloids strychnine and brucine, which are present in concentrations of 1-3%.

Despite its toxicity, the tree's seeds have been utilized, with extreme caution and specialized processing, in various traditional medicinal systems for their stimulant properties. Its distinctive appearance includes a grey, fissured bark and green, glossy leaves, with the fruit resembling a small orange.

Other Names of Kuchla

Nux Vomica
Poison Nut
Strychnine Tree
Crow's Apple

Benefits of Kuchla

Heading

<h3> Absolute Contraindications of Kuchla </h3> <h4>Pregnancy and Breastfeeding [Do not use during pregnancy or lactation]</h4> <ul> <li>🤰</li> <li>Recommendation: Avoid Kuchla entirely in pregnancy and while breastfeeding.</li> <li>Reasoning: The alkaloids (strychnine/brucine) are neurotoxic; maternal poisoning risks severe convulsions and respiratory compromise which endanger both mother and fetus/infant. There are no reliable safety data to define a safe dose in pregnancy or lactation, so it is contraindicated.</li> <li>Scientific_Study_Title: Nux Vomica - LiverTox (NCBI Bookshelf)</li> <li>Scientific_Study_Authors: LiverTox authors / NCBI (editorial monograph)</li> <li>Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/books/NBK589896/</li> <li>Scientific_Study_Excerpt: <p>The LiverTox monograph summarises that Strychnos nux-vomica toxicity derives from strychnine and brucine, which block glycine-mediated inhibitory neurotransmission leading to muscle hyperexcitability, spasms and respiratory failure. The monograph notes the lack of data on fetal risk from strychnine exposure and recommends that maternal treatment follow non-pregnant protocols because maternal toxicity largely determines fetal risk. Given the severity of possible outcomes and absence of safety data for the fetus or breastfed infant, use during pregnancy or lactation is not recommended.</p> <p>Clinicians are advised to manage maternal toxicity aggressively and to consider enhanced fetal monitoring following exposure given potential for severe maternal compromise.</p> </li> </ul> <h4>Epilepsy or pre-existing seizure disorder [Risk of provoking severe seizures]</h4> <ul> <li>⚠️</li> <li>Recommendation: Do not use Kuchla if you have epilepsy or a seizure disorder; avoid it even in herbal mixtures unless supervised by a specialist with monitoring.</li> <li>Reasoning: Strychnine removes inhibitory glycinergic tone and reliably provokes convulsions; even processed herbal preparations have caused tonic spasms when doses were exceeded.</li> <li>Scientific_Study_Title: Herbal medicine causing likely strychnine poisoning.</li> <li>Scientific_Study_Authors: T Y K Chan</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12412642/</li> <li>Scientific_Study_Excerpt: <p>A published case report describes a patient who took a traditional preparation of 'maqianzi' (dried Strychnos seeds) far above recommended limits and developed sudden tonic contractions, carpopedal spasm, breathing difficulty and chest discomfort within an hour. The author highlights that even processed seeds can cause strychnine poisoning when dosing or preparation is incorrect, and that unexplained muscle spasms or convulsions should prompt questioning about herbal use.</p> <p>This case underscores that exposure to S. nux-vomica may precipitate seizures and that people with seizure disorders are at clear risk if exposed to Kuchla or products containing it.</p> </li> </ul> <h4>Children (infants and young children) [High susceptibility to toxicity]</h4> <ul> <li>🧒</li> <li>Recommendation: Never give Kuchla to infants or children; keep seeds and extracts out of reach. If accidental ingestion occurs, seek emergency care immediately.</li> <li>Reasoning: Children tolerate far lower toxic doses; small amounts of seed or contaminated products have produced severe poisoning and fatalities in pediatric cases.</li> <li>Scientific_Study_Title: Plant Family Information - Dietary Supplements (NCBI Bookshelf summary on strychnine toxicity)</li> <li>Scientific_Study_Authors: NCBI / NIH editorial content</li> <li>Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/books/NBK216056/</li> <li>Scientific_Study_Excerpt: <p>Authoritative toxicology summaries state strychnine is highly toxic and that relatively small doses can be fatal in humans; seeds of Strychnos species contain measurable strychnine (approx. 1-3%) and have caused severe poisoning. Pediatric exposures are particularly dangerous because small absolute doses correspond to larger mg/kg amounts in children, increasing risk of convulsions and respiratory failure.</p> <p>The materials recommend treating any suspected ingestion as potentially life-threatening and seeking urgent medical evaluation and toxicology testing when pediatric exposure is possible.</p> </li> </ul> <h4>Raw/unprocessed Kuchla (non-shodhit forms) [Do not use raw seeds]</h4> <ul> <li>🛑</li> <li>Recommendation: Do not use raw/unprocessed Kuchla seeds orally or in powdered form. Only traditionally detoxified (shodhit/sudha) preparations by qualified practitioners are acceptable in classical systems-and even then, under supervision.</li> <li>Reasoning: Processing (shodhana) reduces strychnine content; unprocessed seeds retain high alkaloid levels and are associated with poisoning events.</li> <li>Scientific_Study_Title: Pharmacological evaluation of total alkaloids from nux vomica: effect of reducing strychnine contents.</li> <li>Scientific_Study_Authors: (authors as listed in PubMed abstract)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/24727413/</li> <li>Scientific_Study_Excerpt: <p>Experimental work compared total alkaloid fractions containing native strychnine levels to modified fractions with reduced strychnine. Reducing strychnine markedly lowered toxicity (TAF was ~3.17-fold more toxic than MTAF). Modified fractions (with less strychnine) showed improved pharmacological activity and lower toxicity in animal models, supporting the historical practice of detoxifying the seeds to improve safety.</p> <p>These data provide a scientific basis for the classical requirement that Kuchla be processed before therapeutic use and explain why raw seed ingestion is dangerous.</p> </li> </ul> <h3> Relative Contraindications of Kuchla </h3> <h4>Liver disease or impaired hepatic function [May alter metabolism and increase toxicity]</h4> <ul> <li>🫀</li> <li>Recommendation: Use extreme caution; generally avoid Kuchla if you have known significant liver disease unless a specialist advises otherwise and laboratory monitoring is available.</li> <li>Reasoning: Major alkaloids are metabolized by hepatic enzymes (including CYP isoforms); impaired liver function may raise active alkaloid levels or prolong toxicity.</li> <li>Scientific_Study_Title: In vitro metabolism of brucine by human liver microsomes and its interactions with CYP substrates.</li> <li>Scientific_Study_Authors: Xin Li, Kai Wang, Wei Wei, Yong-yu Liu, Lu Gong</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/23707193/</li> <li>Scientific_Study_Excerpt: <p>Laboratory studies using human liver microsomes found that brucine (a principal alkaloid of S. nux-vomica) is metabolized primarily by CYP3A4 and that brucine itself can inhibit CYP3A4-mediated midazolam hydroxylation at low micromolar concentrations. The findings suggest two clinical concerns: (1) liver impairment could reduce clearance of brucine/strychnine, increasing toxicity; and (2) brucine may interact with other drugs that are CYP3A4 substrates or inhibitors.</p> <p>Therefore pre-existing liver disease or concurrent hepatically cleared drugs increase the risk of adverse outcomes.</p> </li> </ul> <h4>Concomitant use of drugs that lower seizure threshold or increase noradrenergic tone (e.g., certain antidepressants, stimulants)</h4> <ul> <li>💊</li> <li>Recommendation: Avoid combining Kuchla or products containing S. nux-vomica with tricyclic antidepressants, MAO inhibitors, stimulants or other drugs that increase central noradrenergic activity; consult a clinician first.</li> <li>Reasoning: Experimental data show noradrenergic agents and certain antidepressants can potentiate strychnine-induced seizures, increasing risk of severe convulsions.</li> <li>Scientific_Study_Title: Strychnine-induced seizures in mice: the role of noradrenaline.</li> <li>Scientific_Study_Authors: (authors as listed in PubMed abstract)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/7938564/</li> <li>Scientific_Study_Excerpt: <p>Animal experiments demonstrated that drugs increasing central noradrenaline (e.g., DOPS, imipramine, pargyline) significantly shortened the latency and increased incidence of strychnine-induced seizures, while adrenergic antagonists could attenuate them. These results indicate interactions between adrenergic systems and strychnine’s convulsant effects, implying that coadministration with noradrenergic agents or certain antidepressants may raise seizure risk.</p> <p>Clinically, this supports avoiding Kuchla with medications known to raise noradrenergic tone or lower seizure threshold.</p> </li> </ul> <h4>Use with caution in elderly or medically frail patients</h4> <ul> <li>🧓</li> <li>Recommendation: Generally avoid unless supervised; reduced physiological reserve and polypharmacy increase risk of accidental toxicity or drug interactions.</li> <li>Reasoning: Lower body mass, altered drug clearance and multiple comorbidities make older patients more vulnerable to toxic effects and interactions.</li> <li>Scientific_Study_Title: Strychnine toxicity reviews and case literature (examples of severe outcomes in small exposures).</li> <li>Scientific_Study_Authors: Various case reports and reviews (PubMed literature: see case reports on strychnine poisoning).</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27856027/</li> <li>Scientific_Study_Excerpt: <p>Case reports from clinical settings show that strychnine exposure-even from contaminated herbal remedies-may cause acute neuromuscular crises in adults, with rapid onset of trismus, muscular spasms and autonomic disturbances. Variable presentations (including atypical cardiac effects) have been reported, underscoring that vulnerable adults may suffer severe outcomes even from what appears to be modest exposure.</p> <p>Because elderly patients often take multiple medications and have reduced metabolic reserve, they are at elevated risk for adverse events if exposed to Kuchla alkaloids.</p> </li> </ul>

Heading

<h4>Convulsions / severe muscle spasms</h4> <ul> <li>🧠</li> <li>Side effect summary: Kuchla (raw or overdosed preparations) can cause sudden painful muscle contractions, generalized convulsions, and stiffness; these may be triggered by small doses if preparation or dosing is incorrect.</li> <li>Recommendation: Stop exposure immediately and seek emergency care if convulsions or severe spasms develop; anticonvulsant and supportive care are required.</li> <li>Reasoning: Strychnine antagonizes inhibitory glycine receptors → loss of motor inhibition → convulsions.</li> <li>Severity Level: Severe</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Herbal medicine causing likely strychnine poisoning.</li> <li>Scientific_Study_Authors: T Y K Chan</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12412642/</li> <li>Scientific_Study_Excerpt: <p>The case report describes a woman who ingested an excessive dose of processed S. nux-vomica decoction and developed tonic limb contractions, carpopedal spasm, breathing difficulty and chest discomfort within an hour. The author notes the second dose likely became more concentrated on boiling and precipitated toxicity despite prior processing.</p> <p>The report emphasizes that convulsions and muscle spasms are classic features of strychnine poisoning and can occur even with traditional preparations when dosing is exceeded or preparation varies, highlighting the severe nature of this side effect.</p> </li> </ul> <h4>Respiratory compromise (including respiratory muscle spasm leading to asphyxia)</h4> <ul> <li>😮‍💨</li> <li>Side effect summary: Severe exposures can cause spasms of respiratory muscles, leading to breathing failure and death if not supported.</li> <li>Recommendation: Emergency airway and ventilatory support may be lifesaving; call emergency services immediately for suspected severe Kuchla poisoning.</li> <li>Reasoning: Upper motor neuron and respiratory muscle hyperactivity from glycine antagonism can impair ventilatory mechanics and protective reflexes.</li> <li>Severity Level: Severe</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Nux Vomica - LiverTox (NCBI Bookshelf)</li> <li>Scientific_Study_Authors: LiverTox authors / NCBI</li> <li>Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/books/NBK589896/</li> <li>Scientific_Study_Excerpt: <p>Authoritative toxicology summaries note that strychnine blocks post-synaptic glycine receptors causing sustained motor neuron hyperexcitability; this may involve the respiratory musculature leading to repeated convulsions and possible respiratory failure. Fatalities are commonly due to asphyxia from respiratory muscle involvement rather than primary cardiac collapse.</p> <p>Management focuses on aggressive supportive care, anticonvulsants, and isolation from sensory stimuli to avoid triggering recurrent spasms.</p> </li> </ul> <h4>Cardiac effects (arrhythmia, rarely bradycardia)</h4> <ul> <li>❤️</li> <li>Side effect summary: While tachycardia and hypertension are common autonomic signs, atypical presentations including bradycardia and arrhythmias have been reported.</li> <li>Recommendation: Seek urgent care for chest pain, palpitations, fainting or slow heartbeat; monitor ECG and vitals in suspected poisoning.</li> <li>Reasoning: Severe autonomic disturbance during strychnine toxicity can produce variable cardiac responses; individual cases show atypical bradycardia as well as sympathetic overactivity.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: A rare case report of Strychnos nux-vomica poisoning with bradycardia</li> <li>Scientific_Study_Authors: (authors as listed in PubMed abstract)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/29417029/</li> <li>Scientific_Study_Excerpt: <p>The case report documents a patient with mild strychnine poisoning who presented with bradycardia-an atypical finding compared to the usual tachycardia and hypertension associated with strychnine toxicity. The report highlights the variable autonomic effects of the alkaloids and suggests clinicians consider strychnine exposure in unexplained muscular or autonomic presentations.</p> <p>It warns that cardiac signs in S. nux-vomica exposure can range from sympathetic overactivity to paradoxical bradycardia, necessitating close monitoring.</p> </li> </ul> <h4>Gastrointestinal upset (nausea, vomiting, abdominal cramps)</h4> <ul> <li>🤢</li> <li>Side effect summary: Nausea, vomiting and abdominal cramps are commonly reported early symptoms following ingestion of toxic doses; they may precede neurological signs.</li> <li>Recommendation: For mild GI symptoms after known exposure, seek medical advice; for progression to neurological symptoms, go to emergency care.</li> <li>Reasoning: GI irritation and systemic toxicity from alkaloids commonly produce early gastrointestinal symptoms; in reported poisoning cases GI complaints often accompany or precede neuromuscular signs.</li> <li>Severity Level: Mild to Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: A Case of Strychnine Poisoning from a Southeast Asian Herbal Remedy</li> <li>Scientific_Study_Authors: (authors as listed on PubMed abstract)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27856027/</li> <li>Scientific_Study_Excerpt: <p>The clinical case describes a patient who ingested a mislabeled herbal liquid (containing strychnine) and developed early symptoms including jaw pain and abdominal cramping followed by trismus and other neuromuscular signs. The authors caution that herbal and traditional remedies can be sources of strychnine exposure, and gastrointestinal symptoms frequently form part of the early presentation.</p> <p>Patients with GI symptoms after taking Ayurvedic or other herbal products should be asked about possible ingestion of seeds or extracts that might contain S. nux-vomica.</p> </li> </ul>

Heading

<h4>Tricyclic antidepressants / MAO inhibitors / drugs that raise central noradrenaline (e.g., imipramine, DOPS)</h4> <ul> <li>Interaction_Details: Animal studies show these drugs can potentiate strychnine-induced seizures, shortening time to convulsion and increasing incidence; combined exposure raises seizure risk.</li> <li>Severity: Severe</li> <li>Recommendation: Avoid concurrent use of Kuchla with tricyclics, MAO inhibitors, stimulants, or other noradrenergic agents. If exposure is suspected, discuss with a clinician and stop the herbal product immediately.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/7938564/</li> <li>Scientific_Study_Title: Strychnine-induced seizures in mice: the role of noradrenaline.</li> <li>Scientfic_Study_Authors: (authors as listed in PubMed abstract)</li> <li>Scientific_Study_Excerpt: <p>In murine models, administration of noradrenergic agents (e.g., DOPS) and certain antidepressants (e.g., imipramine, pargyline) shortened latency to strychnine-induced seizures and increased seizure incidence; conversely, adrenergic antagonists reduced seizure severity. These mechanistic animal data indicate that drugs which enhance central noradrenergic transmission potentiate strychnine’s convulsant effects.</p> <p>Clinically, this suggests the combination of Kuchla with such medications could meaningfully increase seizure risk and should be avoided or closely supervised.</p> </li> </ul> <h4>CYP3A4 substrates / inhibitors / inducers (many common drugs)</h4> <ul> <li>Interaction_Details: Brucine is metabolized by CYP3A4 and can inhibit CYP3A4 activity in vitro; co-administration may alter blood levels of drugs metabolized by CYP3A4 and vice versa.</li> <li>Severity: Moderate</li> <li>Recommendation: Avoid or use extreme caution when combining Kuchla with drugs that are mainly cleared by CYP3A4 (e.g., certain statins, midazolam, some immunosuppressants). Monitor for altered effects; consult a clinician or pharmacist.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/23707193/</li> <li>Scientific_Study_Title: In vitro metabolism of brucine by human liver microsomes and its interactions with CYP substrates.</li> <li>Scientfic_Study_Authors: Xin Li, Kai Wang, Wei Wei, Yong-yu Liu, Lu Gong</li> <li>Scientific_Study_Excerpt: <p>Human liver microsome studies identified CYP3A4 as a primary enzyme for brucine metabolism; brucine also inhibited CYP3A4-mediated midazolam 1'-hydroxylation with low-micromolar potency. These data indicate a potential for pharmacokinetic interactions between brucine (and thus Kuchla preparations) and drugs that are CYP3A4 substrates or inhibitors, which could increase systemic exposure to either the herbal alkaloids or coadministered medications.</p> <p>Careful review of concomitant medications and monitoring is advised if exposure to Kuchla cannot be avoided.</p> </li> </ul> <h4>Drugs that lower seizure threshold or alter seizure control (e.g., some antipsychotics, bupropion)</h4> <ul> <li>Interaction_Details: Pharmacologic agents that lower seizure threshold may act additively with Kuchla’s glycine-antagonist convulsant effects, increasing seizure frequency or severity.</li> <li>Severity: Moderate</li> <li>Recommendation: Avoid combining Kuchla with drugs known to lower seizure threshold; if unavoidable, consult neurology and monitor closely.</li> <li>Scientific_Study_Available: NA (no direct clinical trial evidence of these specific combinations exists; evidence is mechanistic and from seizure-model studies)</li> <li>Scientific_Study_Link: NA</li> <li>Scientific_Study_Title: NA</li> <li>Scientfic_Study_Authors: NA</li> <li>Scientific_Study_Excerpt: <p>While direct clinical studies of Kuchla combined with specific modern antipsychotics or seizure-lowering drugs are lacking, mechanistic literature and animal models of strychnine-induced seizures demonstrate additive risks when other agents that reduce seizure threshold are present. Clinicians should therefore treat such combinations as potentially hazardous and manage them conservatively.</p> </li> </ul>